9 completed, 1 terminated. 7 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Terminated 1 |
| Phase 1 | 6 | Completed 5, Terminated 1 |
Follow etaracizumab: new trials by email Literature Review of etaracizumab trials Research Report on etaracizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer etaracizumab, bevacizumab - Recurrent Renal Cell Cancer, Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2008-06-01 | 2014-05-15 |
| Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma MEDI-522 - Malignant Melanoma | Phase 1 | Completed | MedImmune LLC | 18 | 2005-05-01 | 2012-03-14 |
| Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis MEDI-522, Placebo - Psoriasis | Phase 2 | Completed | MedImmune LLC | 44 | 2003-12-01 | 2009-04-03 |
| MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid - Prostate Cancer | Phase 2 | Completed | MedImmune LLC | 150 | 2003-12-01 | 2008-01-15 |
| Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate MEDI-522, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | MedImmune LLC | 300 | 2003-09-01 | 2007-11-27 |
| Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma MEDI--522, Integrin + Dacarbazine - Melanoma, Malignant Metastatic Melanoma | Phase 2 | Completed | MedImmune LLC | 110 | 2003-08-01 | 2008-01-15 |
| Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma etaracizumab - Lymphoma, Small Intestine Cancer | Phase 1 | Completed | University of Wisconsin, Madison | 2002-10-01 | 2019-12-13 | |
| Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer MEDI-522 - Cancer | Phase 1 / Phase 2 | Completed | MedImmune LLC | 17 | 2001-07-01 | 2008-05-29 |
| Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer etaracizumab - Colorectal Cancer | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-06-01 | 2013-06-05 | |
| Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors MEDI-522 - Cancer | Phase 1 | Completed | MedImmune LLC | 24 | 2001-03-01 | 2009-01-29 |
Melanoma (2) · Neoplasms (2) · Arthritis, Rheumatoid (1) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1)
MedImmune LLC (7) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Wisconsin, Madison (1)
United States (9) · Canada (3) · Belgium (1) · France (1) · Hungary (1) · Israel (1) · Poland (1) · Russia (1)
Luz Hammershaimb, MD (2) · Barbara White, M.D. (1) · Christopher Ryan (1) · Douglas McNeel, MD, PhD (1) · Krista Arbaugh, Dir., Clinical Ops (1) · Leonard B. Saltz, MD (1) · Luz Hammershaimb, M.D. (1) · Stergios Moschos, MD (1)
P30CA014520 (1), U10CA032102 (1)